Second Sight Medical Products (EYES) Shares Down 3.5%

Shares of Second Sight Medical Products Inc (NASDAQ:EYES) fell 3.5% during trading on Wednesday . The company traded as low as $1.95 and last traded at $1.93. 531,699 shares traded hands during trading, a decline of 32% from the average session volume of 778,494 shares. The stock had previously closed at $2.00.

A number of research firms have recently commented on EYES. HC Wainwright set a $5.00 target price on shares of Second Sight Medical Products and gave the stock a “buy” rating in a research note on Monday. Zacks Investment Research raised shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Monday, January 8th.

An institutional investor recently raised its position in Second Sight Medical Products stock. Vanguard Group Inc. lifted its stake in shares of Second Sight Medical Products Inc (NASDAQ:EYES) by 0.7% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 843,462 shares of the medical device company’s stock after purchasing an additional 5,973 shares during the period. Vanguard Group Inc. owned about 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 12.70% of the company’s stock.

WARNING: This news story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://www.com-unik.info/2018/02/08/second-sight-medical-products-eyes-shares-down-3-5.html.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit